journal
MENU ▼
Read by QxMD icon Read
search

Lancet. Gastroenterology & Hepatology

journal
https://www.readbyqxmd.com/read/30393106/efficacy-and-safety-of-glecaprevir-pibrentasvir-in-patients-with-chronic-hepatitis-c-virus-genotype-5-or-6-infection-endurance-5-6-an-open-label-multicentre-phase-3b-trial
#1
Tarik Asselah, Samuel S Lee, Betty B Yao, Tuan Nguyen, Florence Wong, Adam Mahomed, Seng Gee Lim, Armand Abergel, Joe Sasadeusz, Edward Gane, Neddie Zadeikis, Gretja Schnell, Zhenzhen Zhang, Ariel Porcalla, Federico J Mensa, Kinh Nguyen
BACKGROUND: The pangenotypic direct-acting antiviral regimen of glecaprevir coformulated with pibrentasvir is approved to treat chronic hepatitis C virus (HCV) genotype 1-6 infection in adults. In registrational studies, 84 (99%) of 85 patients with HCV genotype 5 or 6 infection achieved a sustained virological response (SVR) with glecaprevir/pibrentasvir, with no virological failures. To increase the body of data for these less prevalent genotypes, ENDURANCE-5,6 evaluated the efficacy and safety of glecaprevir/pibrentasvir exclusively in patients infected with HCV genotype 5 or 6...
November 1, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30385103/ueg-week-2018
#2
Rob Brierley
No abstract text is available yet for this article.
October 29, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30361080/low-dose-imipramine-for-refractory-functional-dyspepsia-a-randomised-double-blind-placebo-controlled-trial
#3
Pui Kuan Cheong, Alexander C Ford, Cynthia K Y Cheung, Jessica Y L Ching, Yawen Chan, Joseph J Y Sung, Francis K L Chan, Justin C Y Wu
BACKGROUND: Guidelines recommend the use of neuromodulators in patients with functional dyspepsia not responding to proton pump inhibitors (PPIs) and prokinetics; however, there is a lack of data from randomised controlled trials supporting their use. We aimed to assess the safety and efficacy of imipramine, a tricyclic antidepressant (TCA), in treatment-refractory functional dyspepsia. METHODS: In this single-centre, double-blind, randomised controlled trial, we enrolled consecutive patients with Rome II functional dyspepsia aged 18-80 years...
October 22, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30361079/imipramine-for-functional-dyspepsia-a-60-year-journey
#4
Takeshi Kanno, Paul Moayyedi
No abstract text is available yet for this article.
October 22, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30343116/a-composite-disease-activity-index-for-early-drug-development-in-ulcerative-colitis-development-and-validation-of-the-uc-100-score
#5
Vipul Jairath, Jenny Jeyarajah, Guangyong Zou, Claire E Parker, Allan Olson, Reena Khanna, Geert R D'Haens, William J Sandborn, Brian G Feagan
BACKGROUND: Combining clinical, endoscopic, and histological data associated with ulcerative colitis disease activity in a composite index could be a more sensitive way to detect efficacy in small numbers of patients during early drug development. Our aim was to derive and externally validate a novel index for this purpose. METHODS: Index development was done with data from a phase 2 placebo-controlled trial of ozanimod in patients with moderate-to-severe ulcerative colitis (n=179)...
October 17, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30343115/towards-more-efficient-assessment-of-ulcerative-colitis-drugs
#6
Franck Carbonnel
No abstract text is available yet for this article.
October 17, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30318452/watch-and-wait-in-rectal-cancer-is-it-time-to-subclassify-ct3
#7
Rob Glynne-Jones
No abstract text is available yet for this article.
October 11, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30318451/factors-affecting-local-regrowth-after-watch-and-wait-for-patients-with-a-clinical-complete-response-following-chemoradiotherapy-in-rectal-cancer-intercore-consortium-an-individual-participant-data-meta-analysis
#8
Sami A Chadi, Lee Malcomson, Joie Ensor, Richard D Riley, Carlos A Vaccaro, Gustavo L Rossi, Ian R Daniels, Neil J Smart, Melanie E Osborne, Geerard L Beets, Monique Maas, Danielle S Bitterman, Kevin Du, Simon Gollins, Arthur Sun Myint, Fraser M Smith, Mark P Saunders, Nigel Scott, Sarah T O'Dwyer, Rodrigo Otavio de Castro Araujo, Marcus Valadao, Alberto Lopes, Cheng-Wen Hsiao, Chien-Liang Lai, Radhika K Smith, Emily Carter Paulson, Ane Appelt, Anders Jakobsen, Steven D Wexner, Angelita Habr-Gama, Guilherme Sao Julião, Rodiguo Perez, Andrew G Renehan
BACKGROUND: In patients with rectal cancer who achieve clinical complete response after neoadjuvant chemoradiotherapy, watch and wait is a novel management strategy with potential to avoid major surgery. Study-level meta-analyses have reported wide variation in the proportion of patients with local regrowth. We did an individual participant data meta-analysis to investigate factors affecting occurrence of local regrowth. METHODS: We updated search results of a recent systematic review by searching MEDLINE and Embase from Jan 1, 2016, to May 5, 2017, and used expert knowledge to identify published studies reporting on local regrowth in patients with rectal cancer managed by watch and wait after clinical complete response to neoadjuvant chemoradiotherapy...
October 11, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30274836/correction-to-lancet-gastroenterol-hepatol-2018-published-online-sept-24-http-dx-doi-org-10-1016-s2468-1253-18-30269-3
#9
(no author information available yet)
No abstract text is available yet for this article.
September 28, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30274835/hcv-core-antigen-toward-elimination-of-nucleic-acid-testing
#10
Maud Lemoine, Karine Lacombe
No abstract text is available yet for this article.
September 28, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30274834/hcv-core-antigen-as-an-alternative-to-hcv-rna-testing-in-the-era-of-direct-acting-antivirals-retrospective-screening-and-diagnostic-cohort-studies
#11
Marjolein van Tilborg, Saeed H Al Marzooqi, William W L Wong, Raoel Maan, Johannes Vermehren, Benjamin Maasoumy, Tony Mazzulli, Shelly Bolotin, Gary Garber, Fiona Guerra, Christopher R Flud, Matthew Kowgier, Harry L Janssen, Robert J de Knegt, Jean-Michel Pawlotsky, Gavin A Cloherty, Andres Duarte-Rojo, Christoph Sarrazin, Heiner Wedemeyer, Jordan J Feld
BACKGROUND: Direct-acting antivirals for chronic hepatitis C (HCV) infection have reduced the need for on-treatment HCV RNA monitoring. We assessed the accuracy and cost implications of using HCV core antigen testing to replace HCV RNA testing for confirmation of diagnosis, on-treatment monitoring, and determination of sustained virological response (SVR). METHODS: In a retrospective screening cohort study, de-identified residual serum from unselected samples were obtained from commercial laboratories in Ontario, Canada...
September 28, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30262136/bevacizumab-biosimilar-bevz92-versus-reference-bevacizumab-in-combination-with-folfox-or-folfiri-as-first-line-treatment-for-metastatic-colorectal-cancer-a-multicentre-open-label-randomised-controlled-trial
#12
Alvaro Romera, Sergiy Peredpaya, Yaroslav Shparyk, Igor Bondarenko, Giovanni Mendonça Bariani, Kathia Cristina Abdalla, Enrique Roca, Fábio Franke, Felipe Melo Cruz, Anita Ramesh, Vikas Ostwal, Pradeep Shah, Sajeed Abdul Rahuman, Alexandra Paravisini, Camino Huerga, Ana Del Campo García, Susana Millán
BACKGROUND: BEVZ92 is a proposed biosimilar to bevacizumab. The two molecules have similar physicochemical and functional properties in in-vitro and preclinical studies. In this clinical study, we compared the pharmacokinetic profile, efficacy, safety, and immunogenicity of BEVZ92 with reference bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. METHODS: We did a randomised, open-label trial at 15 centres in Argentina, Brazil, India, Spain, and Ukraine...
September 24, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353859/correction-to-lancet-gastroenterol-hepatol-2018-3-778-89
#13
(no author information available yet)
No abstract text is available yet for this article.
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353858/dilated-abdominal-veins-from-budd-chiari-syndrome-and-caval-obstruction
#14
Ross Apostolov, Anthony Schelleman, Paul Gow
No abstract text is available yet for this article.
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353857/stretching-the-boundaries-for-liver-transplant-in-the-21st-century
#15
REVIEW
María Trapero-Marugán, Ester Coelho Little, Marina Berenguer
Given the high waiting list mortality, there is a clear need to identify strategies to increase the number of livers for transplantation. Some strategies require policy changes, whereas others depend on a better understanding of available opportunities. We divided the strategies to increase the number of livers for transplantation into two categories-those aiming to increase the use of organs considered to be of suboptimal quality, and those aiming to increase the use of organs considered to be of suboptimal size...
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353856/mechanisms-of-molecular-resistance-and-predictors-of-response-to-biological-therapy-in-inflammatory-bowel-disease
#16
REVIEW
Raja Atreya, Markus F Neurath
Biological therapy has led to marked improvements in treatment of patients with inflammatory bowel disease, and an increasing number of drugs has been approved for treatment. However, only a subgroup of patients responds to therapy, highlighting the need to identify biomarkers for therapeutic response to allow personalised medicine in inflammatory bowel disease. Potential markers of response to biological therapy have been identified; however, studies also suggest that changes in the composition of immune cell infiltrates in response to therapeutic pressure lead to molecular resistance to these drugs...
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353855/frederick-treves-saviour-of-the-edwardian-era
#17
Talha Khan Burki
No abstract text is available yet for this article.
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353853/meeting-of-the-federation-of-neurogastroenterology-and-motility-2018
#18
Jennifer Thorley
No abstract text is available yet for this article.
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353852/daas-for-hcv-and-risk-of-hepatocellular-carcinoma-current-standpoint
#19
Fabio Piscaglia, Alessandro Granito, Luigi Bolondi
No abstract text is available yet for this article.
November 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30353851/networks-meet-ulcerative-colitis
#20
Franck Carbonnel
No abstract text is available yet for this article.
November 2018: Lancet. Gastroenterology & Hepatology
journal
journal
53645
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"